Received Apr 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
No additional AE; Inbound call from pharmacist to report an AE for GARDASIL-9. Caller noted that a 37 year old female patient had received a 3 dose series of GARDASIL-9 in August 2024, October 2024, December 2024, noting that the interval between the 2nd and 3rd dose; This spontaneous report was received from a pharmacist and refers to a 37-year-old female patient. The patient's pertinent medical history, concurrent conditions, previous drug reactions or allergies and concomitant medications were not reported. On an unspecified date of August 2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (dose, route of administration, lot #, expiration date and anatomical site of injection were not reported). On an unspecified date of October 2024, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (dose, route of administration, lot #, expiration date and anatomical site of injection were not reported). On an unspecified date of December 2024, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (dose, route of administration, lot #, expiration date and anatomical site of injection were not reported). All the vaccines were administered for prophylaxis. The interval between the 2nd and 3rd dose was only within 2 months (Inappropriate schedule of product administration). No additional adverse event was reported (no adverse event).